Literature DB >> 27191208

Inflammatory Bowel Disease Patients' Participation, Attitude and Preferences Toward Exercise.

J Chae1, H I Yang1, B Kim2, S J Park2, J Y Jeon3.   

Abstract

The purpose of the study was to investigate the level of exercise participation in patients with inflammatory bowel disease (IBD) and to investigate their intention, attitude and preference toward exercise. The data of 158 IBD patients that participated in a self-administered survey at Severance Hospital between March 2013 and November 2013 were included in this cross sectional and descriptive analysis. Questionnaires included 3 sections to determine the IBD patient's current exercise participation, attitude toward exercise, and exercise preferences. This study investigated IBD patients both collectively, and according to their specific disease: Crohn's disease (CD) (n=62), Ulcerative colitis (UC) (n=73) and intestinal Behçet's disease (BD) (n=23). IBD patients currently participate in 103 min/week of exercise including mild, moderate and strenuous intensity, with BD patients being the least active, followed by CD, and UC being most active. The majority of IBD patients found exercise to be pleasant (57.7%), beneficial (80.5%), sensible (71.8%), uplifting (61%) and good (70.5%), and 44.4% found exercise to be enjoyable. This study shows the IBD patients' participation, attitude and preferences toward exercise and provides much needed information for the development of evidence based exercise programs that are specific to IBD. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2016        PMID: 27191208     DOI: 10.1055/s-0042-103244

Source DB:  PubMed          Journal:  Int J Sports Med        ISSN: 0172-4622            Impact factor:   3.118


  1 in total

Review 1.  An integrative review of physical activity in adults with inflammatory bowel disease.

Authors:  Suja P Davis; Patricia B Crane; Linda P Bolin; Lee Ann Johnson
Journal:  Intest Res       Date:  2021-01-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.